JAZZ - Jazz Pharmaceuticals PLC - Stock & Dividends
Exchange: USA Stocks • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: IE00B4Q5ZN47
Sleep, Seizure, Cancer, Leukemia, Lymphoma, Hepatic, Neurological
Jazz Pharmaceuticals plc is a biopharmaceutical company that focuses on identifying, developing, and commercializing innovative medicines to address unmet medical needs globally. The company's portfolio includes a range of products that cater to various therapeutic areas, including sleep disorders, oncology, and rare genetic diseases.
In the sleep disorder segment, Jazz Pharmaceuticals offers Xywav and Xyrem to treat cataplexy and excessive daytime sleepiness associated with narcolepsy and idiopathic hypersomnia. These products have revolutionized the treatment landscape for patients struggling with these debilitating conditions.
In the oncology space, the company has developed Zepzelca, a chemotherapy treatment for metastatic small cell lung cancer, and Vyxeos, a therapy for newly-diagnosed acute myeloid leukemia. Additionally, Jazz Pharmaceuticals is working on several pipeline projects, including Zanidatamab, a potential treatment for HER2-expressing gastroesophageal adenocarcinoma, and JZP815, a pan-RAF kinase inhibitor targeting various solid tumors.
Jazz Pharmaceuticals is also committed to developing treatments for rare genetic diseases, such as Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Epidiolex, one of the company's flagship products, has been approved for the treatment of seizures associated with these conditions.
Furthermore, the company has a robust pipeline of early-stage programs, including JZP898, a conditionally-activated interferon alpha molecule, and Suvecaltamide, a potential treatment for Parkinson's disease tremor. Jazz Pharmaceuticals has also entered into strategic collaborations with other companies, such as XL-protein GmbH and Redx Pharma plc, to advance its research and development efforts.
Headquartered in Dublin, Ireland, Jazz Pharmaceuticals was founded in 2003 and has since become a leading player in the biopharmaceutical industry. The company's commitment to innovation and patient-centric approach has enabled it to make a meaningful impact on the lives of patients and their families worldwide.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
JAZZ Stock Overview
Market Cap in USD | 7,242m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Pharmaceuticals |
TER | 0.00% |
IPO / Inception | 2007-06-01 |
JAZZ Stock Ratings
Growth 5y | -29.7 |
Fundamental | 36.9 |
Dividend | |
Rel. Performance vs Sector | -3.42 |
Analysts | 4.32/5 |
Fair Price Momentum | 100.64 USD |
Fair Price DCF | 422.04 USD |
JAZZ Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
JAZZ Growth Ratios
Growth Correlation 3m | -19.8% |
Growth Correlation 12m | -72.2% |
Growth Correlation 5y | -33.2% |
CAGR 5y | -2.38% |
CAGR/Mean DD 5y | -0.11 |
Sharpe Ratio 12m | -0.41 |
Alpha vs SP500 12m | -40.31 |
Beta vs SP500 5y weekly | 0.67 |
ValueRay RSI | 57.54 |
Volatility GJR Garch 1y | 27.34% |
Price / SMA 50 | 0.43% |
Price / SMA 200 | -1.6% |
Current Volume | 337.4k |
Average Volume 20d | 525.8k |
External Links for JAZZ Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of October 29, 2024, the stock is trading at USD 111.37 with a total of 337,420 shares traded.
Over the past week, the price has changed by -1.55%, over one month by +0.40%, over three months by +0.23% and over the past year by -12.32%.
According to ValueRays Forecast Model, JAZZ Jazz Pharmaceuticals PLC will be worth about 108.7 in October 2025. The stock is currently trading at 111.37. This means that the stock has a potential downside of -2.41%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 178.4 | 60.1 |
Analysts Target Price | 201.1 | 80.5 |
ValueRay Target Price | 108.7 | -2.41 |